Wei Lin, the Chief Medical Officer at Revolution Medicines Inc (NASDAQ:RVMD), completed a sale of 2,073 shares of common stock on March 17, 2026, disposing of those shares at $99.48 apiece for a total consideration of $206,222. The transaction was carried out while the stock was trading near $99.29 - following a 156% increase in the share price over the past year.
The disposition was made under a pre-established Rule 10b5-1 trading arrangement that was adopted on December 23, 2024. According to the company filing, the plan was put in place specifically to address tax liabilities arising from the vesting of restricted stock units (RSUs).
After the sale, Wei Lin directly holds 101,366 shares of Revolution Medicines, which the filings indicate include 62,050 RSUs. An InvestingPro analysis cited in company-related commentary notes that the stock presently appears slightly overvalued relative to its Fair Value, and that 12 additional InvestingPro Tips for RVMD are available covering the firm’s financial condition and growth prospects.
Revolution Medicines also released fourth-quarter 2025 financial results that fell short of expectations on the bottom line. The company reported a net loss per share of negative $1.86, compared with the consensus estimate of negative $1.58. Expenses exceeded forecasts in multiple categories: research and development outlays were $21.1 million above estimates, while selling, general, and administrative costs overshot forecasts by $15.4 million.
Despite the earnings shortfall and higher spending, the company finished the quarter with $2.03 billion in cash and investments. That balance was described as strengthened by a strategic partnership with Royalty Pharma.
Financial firms continued to monitor and adjust their views following the report. UBS initiated coverage of Revolution Medicines with a Buy rating, pointing to the potential of the company’s RAS inhibitors in treating a range of solid tumors. Piper Sandler increased its price target to $120 while maintaining an Overweight rating in the wake of the earnings release. Needham raised its price target to $145 and kept a Buy rating, noting the higher costs. Wells Fargo moved its price target to $144, citing confidence in trial progress for daraxon in pancreatic ductal adenocarcinoma.
These analyst actions and the insider sale occurred against the backdrop of a substantial share-price appreciation over the prior year and the company’s recent quarterly results, which combined higher-than-expected expenses with a strong cash position supported by a partnership. The filings and analyst notes present a mixed set of signals for investors evaluating Revolution Medicines’ financial and clinical trajectory.